Genzyme Team Reports Proof-of-concept Data for Expressed RNAi Huntington's Therapy | GenomeWeb

NEW YORK (GenomeWeb) – Researchers from Genzyme this month reported new proof-of-concept data showing that an expressed RNAi approach could be used to both prevent and treat the manifestations of Huntington's disease (HD) in an animal model of the condition.

Though promising, the work is still early stage, cautioned Lisa Stanek, lead author of the study. And while the company is continuing to develop the RNAi-based treatment for HD, clinical studies remain years away, she said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.